Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

28.61 +0.02 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
From Guardant Health, Inc.
Via Business Wire
The Latest Analyst Ratings for Guardant Health
Via Benzinga
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Why Guardant Health Stock Popped Again Today
Wall Street loves this unprofitable biotech. 
Via The Motley Fool
Analyst Expectations for Guardant Health's Future
Via Benzinga
The Latest Analyst Ratings for Guardant Health
Via Benzinga
Preview: Guardant Health's Earnings
Via Benzinga
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
From Guardant Health, Inc.
Via Business Wire
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
This company's fight against a deadly disease could pay off. 
Via The Motley Fool
Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?
The oncology diagnostic companies are looking for better solutions in early cancer diagnosis. 
Via The Motley Fool
Why Guardant Health Stock Jumped 15% This Week
The precision oncology leader benefited from a pair of positive analyst notes this week. Here's what investors need to know. 
Via The Motley Fool
Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst
Shares of Guardant Health Inc (NASDAQ: GH) climbed during the premarket trading session and morning on Wednesday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The... 
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
Exposures COVID-19
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
From Guardant Health, Inc.
Via Business Wire
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Host Investor Day on September 7, 2023
From Guardant Health, Inc.
Via Business Wire
2 Cathie Wood Stocks to Buy and Hold for 10 Years
These companies' growth stories still have plenty of exciting chapters ahead. 
Via The Motley Fool
Guardant Health Stock Sees Renewed Technical Strength
Guardant Health stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 79 to 85. 
Via Investor's Business Daily
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
From Guardant Health, Inc.
Via Business Wire
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
From Guardant Health, Inc.
Via Business Wire
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
From Guardant Health, Inc.
Via Business Wire
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark
On Friday, Guardant Health stock hit a key performance benchmark, with its Relative Strength Rating rising to 82, up from 78 the day before. 
Via Investor's Business Daily
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.